Eli Lilly, Boehringer Ingleheim Report FDA Endocrinologic and Metabolic Drugs Advisory Committee Vote 14-2 Benefits Of Empagliflozin 2.5mg Do Not Outweigh Risks

Benzinga · 11/13/2019 22:10